Hourigan Christopher S, McCarthy Philip, de Lima Marcos
Myeloid Malignancies Section, Hematology Branch, National Heart, Lung and Blood Institute, Bethesda, Maryland.
Blood and Marrow Transplant Program, Roswell Park Cancer Institute, Buffalo, New York.
Biol Blood Marrow Transplant. 2014 Feb;20(2 Suppl):S8-S17. doi: 10.1016/j.bbmt.2014.01.005.
Relapse is a devastating event for patients with hematologic cancers treated with hematopoietic stem cell transplantation. In most situations, relapse treatment options are limited. Maintenance therapy offers the possibility of delaying or avoiding disease recurrence, but its role remains unclear in most conditions that we treat with transplantation. Here, Dr. Hourigan presents an overview of minimal residual disease (MRD) measurement in hematologic malignancies and the applicability of MRD-based post-transplantation interventions. Dr. McCarthy reviews current knowledge of maintenance therapy in the autologous transplantation context, with emphasis on immunologic interventions and immune modulation strategies designed to prevent relapse. Dr. de Lima discusses current lines of investigation in disease recurrence prevention after allogeneic transplantation, focusing on acute myeloid leukemia and myelodysplastic syndrome.
复发对于接受造血干细胞移植治疗的血液系统癌症患者来说是一个毁灭性的事件。在大多数情况下，复发后的治疗选择有限。维持治疗有可能延缓或避免疾病复发，但在我们用移植治疗的大多数情况下，其作用仍不明确。在这里，胡里根博士概述了血液系统恶性肿瘤中微小残留病（MRD）的检测以及基于MRD的移植后干预措施的适用性。麦卡锡博士回顾了自体移植背景下维持治疗的现有知识，重点是旨在预防复发的免疫干预和免疫调节策略。德利马博士讨论了异基因移植后预防疾病复发的当前研究方向，重点是急性髓系白血病和骨髓增生异常综合征。
